glp 1 effects on inflammation Glucagon-like peptide-1 (GLP-1) has established glycemic GLP-1 Agonists in Cardiovascular Diseases:

Studies indicate positive modifications to gut microbiota in just eight weeks of use, supporting both digestive comfort and microbial diversity

Retrieved from Feier, C

Blood glucose monitoring helps identify hypoglycemia or significant fluctuations

GLP-1RAs and clinical trials in NAFLD Lixisenatide In a systematic meta-analysis including 12 randomized controlled trials (RCTs) comparing lixisenatide to placebo or active interventions in T2D, lixisenatide was reported to normalize levels of alanine aminotransferase (ALT) in a greater proportion of overweight and obese patients with T2D than comparators (54)

Always speak to your healthcare provider before beginning any new treatment